Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option
with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple
relapses after chemotherapy. However, all patients with an indication of allo-HSC can not
benefit because of two limitations: the toxicity of the treatment and graft shortage
available.
Phase:
N/A
Details
Lead Sponsor:
Association for Training, Education, and Research in Hematology, Immunology, and Transplantation